- Bayer announced Health Canada expanded Lynkuet (elinzanetant) to treat moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in breast cancer, making it Canada’s first approved option for this population.
- The approval builds on Lynkuet’s July 2025 authorization for menopause-related VMS. Hot flashes, night sweats and sleep disruption can significantly affect quality of life during breast cancer treatment.
- The Phase III OASIS-4 trial evaluated elinzanetant in women receiving adjuvant endocrine therapy with moderate to severe VMS. Across the OASIS program, it significantly reduced VMS frequency versus placebo.
- Canadian research found moderate to severe VMS were linked to 30.2% impairment in work productivity and 35.7% impairment in daily activities, highlighting the need for non-hormonal treatment options in this population.
Takeaways:
The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for treatment‑induced hot flashes and night sweats, which can be a major driver of poor adherence to endocrine therapy. By addressing a high‑burden side effect that affects work and daily functioning, Lynkuet could improve persistence on AET, broaden the addressable market for VMS therapies beyond natural menopause, and encourage earlier adoption of non‑hormonal agents in oncology supportive care.
Source: Businesswire
